1. Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer
- Author
-
Makoto Kudo, Atsushi Miyasaka, Masaki Yamamoto, Tatsuya Muraoka, Tatsuya Inoue, Ayami Kaneko, Saki Manabe, Kunihiko Shibata, Shuhei Teranishi, Ryota Ushio, Ami Izawa, Yasuyuki Sugiura, Takeshi Kaneko, Hironori Tamura, Hiromi Kanaoka, and Nobuyuki Hirama
- Subjects
Male ,HLA-DR4 ,medicine.medical_specialty ,Lung Neoplasms ,medicine.drug_class ,medicine.medical_treatment ,Case Report ,030204 cardiovascular system & hematology ,Gastroenterology ,Uveitis ,03 medical and health sciences ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Internal Medicine ,Humans ,Medicine ,Lung cancer ,Adrenocortical Insufficiency ,adrenocortical insufficiency ,Chemotherapy ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Vogt-Koyanagi-Harada-like syndrome ,eye diseases ,Discontinuation ,Hearing disorder ,Nivolumab ,non-small-cell lung cancer ,immune-related adverse events ,Corticosteroid ,Adenocarcinoma ,030211 gastroenterology & hepatology ,Uveomeningoencephalitic Syndrome ,business - Abstract
A 58-year-old man was diagnosed with lung adenocarcinoma with a tumor proportion score of 10%. After six cycles of second-line chemotherapy with nivolumab, he achieved a complete response (CR) but developed uveitis and sensorineural hearing disorder, which were consistent with Vogt-Koyanagi-Harada (VKH)-like syndrome. Simultaneously, pituitary adrenocortical insufficiency was identified. Nivolumab discontinuation and systemic corticosteroid administration resolved these immune-related adverse events (irAEs). The patient has maintained a CR without any chemotherapy for approximately two years. We herein report a patient with a long-term progression-free survival despite chemotherapy discontinuation due to irAEs, including VKH-like syndrome, which were appropriately managed.
- Published
- 2021